OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply Side
OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply-Side
Share
With US automotive media ad spend projected to surpass $31 billion in 2025, OpenX — through the integration of Polk's advanced analytics solutions — empowers auto buyers to measure and optimize campaigns, delivering real-time attribution tied to actual vehicle transactions.
The integration also includes Polk's predictive audiences, which, unlike traditional solutions that rely on sample data or modeled assumptions, are rooted in more than 30 years of ownership history and scored and trained against census-level vehicle transactions. Together with OpenX's people-based identity graph and premium cross-inventory format, this partnership ensures greater targeting accuracy and meaningful campaign results.
With OpenXSelect™, a curation and supply-side targeting platform that makes media buying easier, faster, and more precise across channels, and Polk's 2,000+ auto segments built from a rich understanding of auto buyers, media buyers get high-fidelity offline matching, insights to optimize campaigns in-flight, and accurate closed-loop measurement and attribution across CTV, display, and out-of-home campaigns.
'Our mission is to deliver the industry's best automotive insights and data that empowers our users to connect more effectively with their customers,' says Joe Kyriakoza, VP and General Manager Polk Automotive Solutions at S&P Global Mobility. 'Integrating Polk's automotive intelligence into OpenXSelect extends the reach and performance of Polk solutions, giving marketers the insights and scale needed to drive better business outcomes while streamlining campaign setup.'
OpenX has led curation and supply-side targeting since 2018, when it launched the industry's first and largest independent supply-side identity graph. Today, OpenXSelect pairs premium omnichannel inventory with turnkey audience, behavioral, attention, and sustainability data and over 200,000 direct publisher sites and apps, delivering unmatched scale across CTV, native, app, and web inventory.
'This integration marks a major milestone in delivering more advanced, higher-performing tools,' said Brian Chisholm, SVP of Strategic Partnerships at OpenX. 'Supply-side targeting and curation are maturing rapidly. Targeting has been a key focus for us, and the ability to measure outcomes with Polk delivers significant advertiser value.'
About OpenX
OpenX is an independent omnichannel supply-side platform (SSP) and a global leader in supply-side curation, transparency, and sustainability. Through its 100% cloud-based tech stack, OpenX powers advertising across CTV, app, mobile web, and desktop, enabling publishers to deliver marketers improved performance and dynamic future-proofed solutions. With a 17-year track record of programmatic innovation, OpenX is a direct and trusted partner of the world's largest publishers, working with more than 200,000 premium publisher domains and over 100,000 advertisers. As the market leader in sustainability, OpenX was the first adtech company certified as CarbonNeutral™ and third-party verified for achieving its SBTi Net-Zero targets. Learn more at www.openx.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
21 minutes ago
- CNBC
These buy-rated stocks are undervalued and can perform in the future, BMO says
As the stock market continues to churn near all-time highs, BMO Capital Markets has some ideas for individual stocks that can work in the future. The backdrop for BMO's recommendations: U.S. stocks recently hitting all-time highs, a stunning recovery from the early April sell-off on the back of President Donald Trump's imposition of higher tariffs. Now investors ask if there's cause for optimism that more gains are in store — or if the market is too overbought. But BMO is confident, with chief investment strategist Brian Belski telling clients in a recent note that U.S. stocks remain in a bull market. While he acknowledged some valuation measures are above their historical average, he said they're probably not as severe as they look. "We understand the sentiment, but we disagree with any suggestion that U.S. stocks may be headed for a severe or prolonged downturn based on valuation alone," Belski wrote. "Instead, we continue to recommend that investors 'stay the course' and use any potential periods of market weakness as a buying opportunity." Belski said those investors who are worried about valuations can protect themselves by looking at companies whose shares sell at lower price-to-earnings ratios, rather than higher-multiple growth stocks. To find such stocks, BMO screened for S & P 500 stocks that the bank has an outperform rating on and with a forward price-to-earnings multiple for the next 12 months below 15. Here's are several that turned up: Pharmaceutical company Pfizer made it on to the BMO screen. The maker of the Eliquis blood thinner and Paxlovid treatment for Covid last week said the Food and Drug Administration is considering removing its authorization of the company's Covid-19 vaccine for healthy children under the age of 5. Pfizer has fallen more than 5% in 2025, on track for its fourth straight annual decline, although it yields almost 7%. While the majority of analysts polled by LSEG have a hold rating, the average price target implies shares can rally more than 16% in the next year. Constellation Brands , the brewer of Corona and Modelo beer, also met the BMO criteria. Shares have fallen 24% so far in 2025, on pace for their worst year since 2018. The stock yields almost 2.5%. Despite this year's rough patch, Wall Street expects a recovery. The consensus rating among analysts surveyed by LSEG is buy, with an average price target projecting about 26% upside over the next year.
Business Wire
an hour ago
- Business Wire
Xspray Pharma Submits XS003 to the FDA – The Company's Second Product Candidate from the HyNap Platform
STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic myeloid leukemia (CML). The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. XS003 demonstrates the lowest documented food interaction within the nilotinib class and improved dose linearity, which gives physicians greater predictability when adjusting the dose, enabling more consistent exposure and potentially reducing the risk of side effects. Due to XS003's improved food interaction profile, the warning about three hours of fasting, currently included in the reference product's so-called boxed warning, is not expected to apply to XS003. This may simplify treatment and improve adherence. XS003 is an improved formulation of nilotinib (Tasigna®) and developed using the company's proprietary HyNap™ technology. 'Patients with chronic leukemia live not only with their disease—but also with side effects from medications, often related to food interaction and concomitant treatments. Our proprietary HyNap technology addresses these challenges and may help improve treatment outcomes and quality of life for this patient group. Our goal is to develop and commercialize a portfolio of next-generation Protein Kinase Inhibitor products with stable absorption, low variability, and minimal food interaction. With XS003, we now have two product candidates under FDA review with strong clinical potential, addressing a total U.S. market worth USD 2.7 billion,' says Per Andersson, CEO of Xspray Pharma. Data from registration studies demonstrate bioequivalence with the reference product, despite XS003 being administered at less than half the dose of the reference product. In addition, the studies confirm clearly improved dose linearity, which may provide physicians with better predictability when adjusting doses, and thereby a greater ability to achieve improved treatment outcomes. The uptake of XS003 is only slightly affected when taken with food, while the reference product is significantly affected as reflected in their label (28% vs. 82%). This may indicate improved control and a lower risk of side effects when taken with food. Xspray expects the FDA to initiate its review within 60 days, with a regulatory decision anticipated approximately eight months thereafter. Global 2024 nilotinib sales reached USD 1.67 billion in 2024, of which USD 850 million came from the U.S. About Xspray Pharma Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit
Yahoo
an hour ago
- Yahoo
Is AI Market Forming a Bubble? Nasdaq-100 ETF in Focus
OpenAI CEO Sam Altman has recently suggested that the artificial intelligence (AI) industry is currently experiencing a bubble fear, as quoted on CNBC. He explained that while AI represents one of the most significant technological shifts in decades, the excitement around it has led to overinflated expectations from investors. Altman sees similarity between the current environment to the dot-com boom of the late 1990s, which was hit hard when many Internet companies failed to materialize the euphoria into profits. Warnings From Industry Leaders Altman's remarks mirror concerns raised by other influential figures in business and finance. Alibaba co-founder Joe Tsai, Bridgewater Associates founder Ray Dalio, and Apollo Global Management's chief economist Torsten Slok have all cautioned that AI valuations may be overheating. Slok has even argued that the present AI surge could be more inflated than the Internet bubble, pointing out that today's most valuable companies in the S&P 500 are more stretched in valuation than they were during the 1990s. Note that between March 2000 and October 2002, the Nasdaq lost nearly 80% of its value. Analysts Divided on the Bubble Narrative Not all analysts think that the entire AI market has entered bubble territory. Some experts argue that the fundamentals of AI and semiconductor supply chains remain strong and that the long-term growth prospects justify continued investment. However, many fear that capital is being invested in companies with weaker fundamentals, which may cause problems later on. Rising Competition From Low-Cost Chinese Peers The concerns intensified earlier this year when the 'Magnificent Seven' had fallen from grace due to factors such as new, cheaper-cost AI entrants (e.g., DeepSeek) and individual companies' ability to handle broader macro uncertainty. DeepSeek, a Chinese startup developing AI models, revealed in late January that training the R1 model cost just $5.6 million, significantly less than the $100 million required to train OpenAI's GPT-4 model. On the other hand, Alibaba BABA introduced the QwQ-32B model, an AI system that rivals DeepSeek but requires only a fraction of the data. Such advancements triggered doubts that the huge capital investments deployed by U.S. tech majors to develop AI technologies will generate the expected returns at all. Rocky Journey of ChatGPT-Fame Open AI Although the credibility of these claims has been questioned, the development has raised questions about whether current spending levels in AI are sustainable. Despite OpenAI's huge success and its annual recurring revenue projection to top $20 billion this year, the company remains unprofitable. The rollout of its latest GPT-5 model has also been anything but smooth, with some users finding it less intuitive than expected. Nasdaq-100 ETF in Focus Most AI biggies have exposure to the Nasdaq-100-based exchange-traded fund (ETF) Invesco QQQ Trust, Series 1 QQQ. The P/E ratio of QQQ stands at 59.27X. The 10-year range of the P/E ratio is 19.7X to 59.46X. The median P/E of the past 10 years is 25.8X. This shows the overvaluation concerns associated with QQQ. However, the price-to-book (P/B) ratio of QQQ is currently 3.6X, which is the lowest value considering the past 10-year range. The 10-year median P/B is 6.03X, per Moreover, with the Fed likely to cut rates in the coming months amid a weakening labor market, the growth stocks of QQQ should see some tailwinds. Hence, the sudden crash of AI euphoria (if there is any) may not hurt QQQ that hard. Still, investors should be mindful of relentless AI investing going forward. Their portfolio may need diversification at the current juncture. Note that the annualized return of QQQ is 18.78% over the past 10 years, while it is 21.23% over the past three years (due to the AI rally). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco QQQ (QQQ): ETF Research Reports Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Inicia sesión para acceder a tu portafolio
